机构地区：[1]厦门大学附属第一医院厦门市肿瘤医院,福建厦门361000
出 处：《中外医学研究》2018年第19期8-11,共4页CHINESE AND FOREIGN MEDICAL RESEARCH
摘 要：目的:观察重组人血管内皮抑素注射液(恩度)联合化疗治疗胃癌腹膜转移的有效性和安全性。方法:选取70例胃癌腹膜转移的患者,随机分为研究组(n=36)和对照组(n=34)。研究方案:两组均接受多西他赛75 mg/m^2静脉化疗,替吉奥胶囊(1.25 m^2<体表面积<1.5 m^2,50mg/次;体表面积≥1.5 m^2,60 mg/次,2次/d;连续14 d)口服,同时顺铂40 mg/m^2腹腔灌注化疗。研究组在顺铂腹腔灌注前3 d联合恩度60 mg/次,腹腔灌注第1、3天。评价不良反应,每2个周期评价治疗效果,化疗直至疾病进展或毒性不能耐受,最多治疗6个周期。结果:两组均无完全缓解患者,研究组部分缓解率25.0%(9/36),疾病稳定率55.6%(20/36),疾病控制率80.6%(29/36),对照组部分缓解率17.6%(6/34),疾病稳定率32.4%(11/34),疾病控制率50.0%(17/34),研究组疾病控制率高于对照组,差异有统计学意义(P=0.007)。研究组中位无进展生存时间、中位总生存时间均优于对照组,差异均有统计学意义(P=0.009、0.023)。两组各不良反应发生率比较,差异均无统计学意义(P>0.05),均无化疗相关死亡。结论:恩度联合化疗可提高治疗胃癌腹膜转移的效果,延长生存期,不增加明显不良反应。Objective:To observe the efficacy and safety of Recombinant Human Endostatin Injection(Endostar)combined with chemotherapy in the treatment of peritoneal metastasis of gastric cancer.Method:A total of 70 patients with peritoneal metastasis of gastric cancer were randomly divided into study group(36 cases)and control group(34 cases).The patients of two groups were treated with Docetaxel 75 mg/m2 intravenous chemotherapy,Tegafur Capsule(1.25 m2<body surface area<1.5 m2,50 mg each time;body surface area over than 1.5 m2,60 mg each time,2 times each day;14 days of treatment),and Cisplatin 40 mg/m2 each time intraperitoneal perfusion chemotherapy.The study group received Endostar 60 mg each time intraperitoneal perfusion on day 1 and day 3 three days before intraperitoneal infusion of Cisplatin.Adverse reactions were evaluated,and therapeutic effects were evaluated every 2 cycles,Chemotherapy until disease progression or toxicity intolerance,and the treatment lasted for 6 cycles at most.Result:There was no complete remission in the two groups.The partial remission rate of the study group was 25.0%(9/36),the disease stability rate was 55.6%(20/36),the disease control rate was 80.6%(29/36),the control group partial remission rate was 17.6%(6/34),the disease stability rate was 32.4%(11/34),the disease control rate was 50.0%(17/34);the disease stability rate in the study group was higher than that in the control group,and the difference was statistically significant(P=0.007).The median progression free survival time and the median overall survival time were better than those of the control group,the differences were statistically significant(P=0.009、0.023).There were no significant differences of the incidence of adverse reactions between the two groups(P>0.05),and there was no chemotherapy related death.Conclusion:Endostar combined with chemotherapy in the treatment of peritoneal metastasis of gastric cancer is more effective than conventional chemotherapy,it can prolong the survival time and tolerable adverse reaction
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
